CAS: 27048-04-0; 6-Chloro-3-Nitropyridin-2-Amine

相似化合物

40851-95-4 33742-70-0 203794-33-6

上下游产品

2-chloro-5-nitropyridine 2,6-dicholoro-3-nitropyridine 2-amino-3-nitro-6-hydroxypyridine 2-chloro-6-methoxy-3-nitropyridine 2-acetamido-6-chloro-3-nitropyridine 2-amino-3-nitro-6-(p-fluoro-benzylamino)-pyridine 6-chloropyridine-2,3-diamine 6-(2-Methyl-benzyl)-3-nitro-pyridine-2,6-diamineN6-(2-Methyl-benzyl)-3-nitro-pyridine-2,6-diamine

2,6-二氯吡啶置于ammonium Hydroxide,硫酸,硝酸体系中,用 异丙醇 用作溶剂,化学反应 72.0H,反应生成2-氨基-3-硝基-6-氯吡啶
参考文献:与钾kv7通道开放活性有关但与肝细胞毒性无关的止痛药氟吡汀n修饰衍生物的氧化电位
标题:与钾kv7通道开放活性有关但与肝细胞毒性无关的止痛药氟吡汀n修饰衍生物的氧化电位
摘要:神经元电压门控性钾离子通道(k V)的开放剂作为治疗疼痛(氟吡汀)和癫痫病(瑞替加滨)的治疗剂受到关注.为了更好地了解氟吡汀的作用机理和毒性,我们合成了九种具有不同氧化还原行为的新型类似物.氟吡汀可被氧化代谢为氮杂醌二亚胺;因此,通过循环伏安法测定了氟吡汀及其类似物的氧化电位.K V 7.2 / 3(kcnq2 / 3)打开活性是通过已建立的测定法来确定的,这些测定法过度表达了这些通道的hek293细胞.发现化合物的氧化电位与其ec 50之间存在联系钾通道开放活性的数值.另一方面,在转基因小鼠肝细胞(tamh)的培养物中,氧化电位与细胞毒性之间没有相关性.这些结果支持了氟吡汀的氧化代谢产物有助于作用机理的想法,类似于最近对乙酰氨基酚(对乙酰氨基酚)的提议,但对肝毒性没有影响.
Doi:10.1002/cmdc.201402442

专利信息

专利号:US-2022267323-A1
优先权日:2019-07-23
标题 :Synthesis of bicyclic inhibitors of histone deacetylase
发明人：FULLER NATHAN OLIVER; HEWITT MICHAEL CHARLES; ASSELIN SYLVIE M; LUKE WAYNE DOUGLAS
权利人:ALKERMES INC
摘要:Provided herein are synthetic methods for the preparation of compounds having the Formula: (I) and (I′) and salts thereof.

专利号:US-9834556-B2
优先权日:2014-03-24
标题 :Process of preparing 3-(3-(4-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-B]pyridin-2-YL)pyridin-2-amine
发明人：BATES CRAIG; CHEN JIAN-XIE; MAO JIANMIN; REED DAVID P
权利人:ARQULE INC
摘要:The present invention is directed to a processes for the synthesis of 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine:

专利号:WO-2024168196-A1
优先权日:2023-02-08
标 题:Systems and methods for enzymatic synthesis of polynucleotides containing non-standard nucleotide basepairs
发明人：MARCHAND JORGE; KAWABE HINAKO
权利人:UNIV WASHINGTON
摘要:Systems and methods for generating defined base pairs in a sequence-defined library format that include at least one non-standard nucleotide in a base pair. Non-standard base pairs can be created using a nucleic acid polymerase ( e.g. , DNA polymerase, RNA polymerase, terminal deoxynucleotide polymerase) for blunt-end tailing addition of the non-standard base, which then can be ligated to another nucleotide end. The nucleotide sequences containing non-standard base pairs can be used to generate libraries for basecalling models of the non-standard base with next-generation sequencing (NGS) platforms and sequencing non-standard nucleotide sequences, including xenonucleotide (XNAs).

专利号:US-2024400552-A1
优先权日:2016-11-11
标题 :Heterocyclic modulators of lipid synthesis
发明人：BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by dysregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

专利号:US-11622968-B2
优先权日:2011-03-08
标 题:Heterocyclic modulators of lipid synthesis
发明人：BUCKLEY DOUGLAS; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

专利号:US-11034690-B2
优先权日:2016-11-11
标 题:Heterocyclic modulators of lipid synthesis
发明人：BUCKLEY DOUGLAS I; DUKE GREGORY; WAGMAN ALLAN S; EVANCHIK MARC; MCDOWELL ROBERT S
权利人:SAGIMET BIOSCIENCES INC; SAGINIET BIOSCIENCES INC
摘要:Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).